台湾食品药品管理局批准珠穆朗玛峰药物公司 NEFECON 用于IGAN 高危成年人的治疗。 Taiwan's FDA approves Everest Medicines' NEFECON® for IgAN treatment in adults at risk.

艾佛雷斯特药物已获得台湾食品和药物管理局对NEFECON®的批准,该药物用于治疗患有疾病进展风险的成年人中原发性免疫球蛋白A瘤 (IgAN). Everest Medicines has received approval from Taiwan's Food and Drug Administration for NEFECON®, a treatment for primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. 在新加坡、香港和中国内地也作了类似批准之后,这标志着该药物在亚洲获得第五次批准。 This marks the drug's fifth approval in Asia, following similar approvals in Singapore, Hong Kong, and Mainland China. NEFECONÁ在保持肾功能和减少蛋白质尿症方面表现出了效力,并计划在亚洲进一步扩大。 NEFECON® has shown effectiveness in preserving kidney function and reducing proteinuria, with plans for further expansion in Asia.